Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.

Colovic N, Suvajdzic N, Kraguljac Kurtovic N, Djordjevic V, Dencic Fekete M, Drulovic J, Vidovic A, Tomin D.

Biomed Pharmacother. 2012 Apr;66(3):173-4. doi: 10.1016/j.biopha.2011.10.004. Epub 2011 Dec 31.

PMID:
22440894
[PubMed - indexed for MEDLINE]
2.

Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients.

Voltz R, Starck M, Zingler V, Strupp M, Kolb HJ.

Mult Scler. 2004 Aug;10(4):472-4. Review.

PMID:
15327049
[PubMed - indexed for MEDLINE]
3.

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.

Pascual AM, Téllez N, Boscá I, Mallada J, Belenguer A, Abellán I, Sempere AP, Fernández P, Magraner MJ, Coret F, Sanz MA, Montalbán X, Casanova B.

Mult Scler. 2009 Nov;15(11):1303-10. doi: 10.1177/1352458509107015. Epub 2009 Oct 13.

PMID:
19825889
[PubMed - indexed for MEDLINE]
4.

Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.

Brassat D, Recher C, Waubant E, Le Page E, Rigal-Huguet F, Laurent G, Edan G, Clanet M.

Neurology. 2002 Sep 24;59(6):954-5.

PMID:
12297591
[PubMed - indexed for MEDLINE]
5.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
[PubMed - indexed for MEDLINE]
6.

Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

Ellis R, Boggild M.

Mult Scler. 2009 Apr;15(4):505-8. doi: 10.1177/1352458508100967. Epub 2009 Feb 27.

PMID:
19251838
[PubMed - indexed for MEDLINE]
7.

Mitoxantrone-related acute leukemia in two MS patients.

Pielen A, Goffette S, Van Pesch V, Gille M, Sindic CJ.

Acta Neurol Belg. 2008 Sep;108(3):99-102.

PMID:
19115673
[PubMed - indexed for MEDLINE]
8.

Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.

Kröger N, Damon L, Zander AR, Wandt H, Derigs G, Ferrante P, Demirer T, Rosti G; Solid Tumor Working Party of the European Group for Blood and Marrow Transplantation; German Adjuvant Breast Cancer Study Group; University of California, San Francisco.

Bone Marrow Transplant. 2003 Dec;32(12):1153-7. Review.

PMID:
14647269
[PubMed - indexed for MEDLINE]
9.

Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.

Ramkumar B, Chadha MK, Barcos M, Sait SN, Heyman MR, Baer MR.

Cancer Genet Cytogenet. 2008 Apr 15;182(2):126-9. doi: 10.1016/j.cancergencyto.2008.01.004. Erratum in: Cancer Genet Cytogenet. 2008 Oct 15;186(2):130.

PMID:
18406875
[PubMed - indexed for MEDLINE]
10.

Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.

Le Page E, Leray E, Edan G; French Mitoxantrone Safety Group.

Mult Scler. 2011 Jul;17(7):867-75. doi: 10.1177/1352458511398371. Epub 2011 Feb 15.

PMID:
21325016
[PubMed - indexed for MEDLINE]
11.

[Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia].

Meyer C, Ansorge N, Siglienti I, Salmen S, Stroet A, Nückel H, Dührsen U, Ritter PR, Schmidt WE, Gold R, Chan A.

Nervenarzt. 2010 Dec;81(12):1483-9. doi: 10.1007/s00115-010-3041-5. German.

PMID:
21079910
[PubMed - indexed for MEDLINE]
12.

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.

Ghalie RG, Mauch E, Edan G, Hartung HP, Gonsette RE, Eisenmann S, Le Page E, Butine MD, De Goodkin DE.

Mult Scler. 2002 Oct;8(5):441-5. Review.

PMID:
12356214
[PubMed - indexed for MEDLINE]
13.

Evaluation of mitoxantrone for the treatment of multiple sclerosis.

Jain KK.

Expert Opin Investig Drugs. 2000 May;9(5):1139-49. Review.

PMID:
11060734
[PubMed - indexed for MEDLINE]
14.

Mitoxantrone therapy in rapidly worsening multiple sclerosis.

Benesova Y, Stourac P, Beranek M, Kadanka Z.

Bratisl Lek Listy. 2005;106(3):141-3.

PMID:
16026151
[PubMed - indexed for MEDLINE]
15.

Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis.

Mulroy E, Joyce E, Scott J, Melling J, Goggin C, Mahon N, O'Rourke K, Lynch T.

Eur Neurol. 2012;67(1):45-7. doi: 10.1159/000334101. Epub 2011 Dec 9.

PMID:
22156316
[PubMed - indexed for MEDLINE]
16.

Therapy-related acute nonlymphoblastic leukemia following mitoxantrone therapy in a patient with multiple sclerosis.

Sumrall A, Dreiling B.

J Miss State Med Assoc. 2007 Jul;48(7):206-7.

PMID:
17939254
[PubMed - indexed for MEDLINE]
17.

Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy.

Linassier C, Barin C, Calais G, Letortorec S, Brémond JL, Delain M, Petit A, Georget MT, Cartron G, Raban N, Benboubker L, Leloup R, Binet C, Lamagnère JP, Colombat P.

Ann Oncol. 2000 Oct;11(10):1289-94.

PMID:
11106118
[PubMed - indexed for MEDLINE]
Free Article
18.

Acute myeloid leukaemia induced by mitoxantrone: case report.

Arruda WO, Montú MB, de Oliveira Mde S, Ramina R.

Arq Neuropsiquiatr. 2005 Jun;63(2A):327-9.

PMID:
16100984
[PubMed - indexed for MEDLINE]
Free Article
19.

[Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone].

Nollet S, Berger E, Deconinck E, Baldauf E, Rumbach L.

Rev Neurol (Paris). 2006 Feb;162(2):195-9. French.

PMID:
16518259
[PubMed - indexed for MEDLINE]
20.

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Neurology. 2010 May 4;74(18):1463-70. doi: 10.1212/WNL.0b013e3181dc1ae0. Review.

PMID:
20439849
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk